Navigation Links
Bluestar Silicones Presents Elastomer Solutions At Medical Design And Manufacturing (MD&M) East Show
Date:6/13/2013

PHILADELPHIA, June 13, 2013 /PRNewswire/ -- Bluestar Silicones will showcase its new Silbione® silicone elastomer solutions, including low durometer liquid silicone rubber (LSR) and self-bleeding LSR, at the upcoming Medical Design & Manufacturing (MD&M) East Conference (Booth #3744), June 18-20.  

Bluestar Silicones' new 1 Shore A (ShA) hardness product, Silbione LSR 4301, uniquely combines strong physical properties and easy processing in a low-durometer material. This product rounds out the company's 5 and 10 ShA soft LSR range, delivering high tear strength and elongation for soft cushioning and vibration dampening applications.

The company also introduces its new Silbione LSR 4755, which creates a lubricious surface on the molded part after vulcanization.  This lubricious material is designed to minimize friction and prevent slit healing in application.  Built into the bulk LSR formulation, the self bleeding lubricity of Silbione LSR 4755 eliminates the need for a secondary coating process to reduce coefficient of friction, reducing costs and improving cycle time for the part manufacturer.

"Bluestar Silicones is excited to present these specialty silicone solutions to the market," according to Karen O'Keefe, market manager, North America.  "The high performance physicals of our low durometer LSRs are unmatched in the industry.  And, our self-bleeding material provides a solution to the inherent non-slip surface of LSRs, improving productivity in automated assembly and part performance in select applications."

These specialty LSR products are manufactured in a clean room environment at Bluestar Silicones' new 226,000-sq-ft facility in York, S.C., and incorporate the distinctive advantages of Bluestar Silicones' standard LSR product line, including easy processing, easy release, and high-performance physic
'/>"/>

SOURCE Bluestar Silicones
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
2. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
3. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the FedEx St. Jude Classic
4. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
5. NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
8. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
9. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
10. BioElectronics Presents FDA Reclassification Panel
11. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... May 29, 2015 Research and Markets ... the "Global A Dialyzer Reprocessing Machine (A ... to their offering. The Global A ... Report 2014 is a professional and in-depth study ... reprocessing machine industry. The report provides a ...
(Date:6/1/2015)... CAMBRIDGE, Mass. , June 1, 2015  Boston ... compounds designed to target cancer stem cell (CSC) pathways, ... BBI608 and BBI503 in multiple tumor types at the ... in Chicago . Data ... an orally-administered investigational agent that targets STAT3, leading to ...
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
Breaking Medicine Technology:Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... NEW YORK , July 6 Reportlinker.com announces that a ... , , ... and leading players , , ... http://www.reportlinker.com/p0233961/Opportunities-in-Non-Surgical-Bio-Implants-Marketed-injectable-biomaterials-applications-and-leading-players.html , , , ...
... OXFORD, England and LANGHORNE, ... a transatlantic specialty pharmaceutical company focused on,oncology, pain control ... Japanese development and commercialization rights to its oncology therapy,Erwinase(R) ... product partnership EUSA has established in Japan . ...
Cached Medicine Technology:Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 2Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 3Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 4Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 5Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 6Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 7Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 8Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 9Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 10Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players 11EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical 2EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical 3
(Date:6/1/2015)... IPSWICH, Mass. (PRWEB) June 01, 2015 ... decision support solutions, today introduced DynaMed Plus™ , ... and other medical professionals. It provides clinicians with the ... determine optimal patient care paths. , DynaMed Plus ... the market and includes the most frequently updated evidence-based ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 Note: ... new development in breast cancer prevention. , A phase ... suggests that postmenopausal women with ductal carcinoma in situ ... treatment and prevention. , The study (NSABP B-35/NRG Oncology) ... who completed the standard five-year treatment with tamoxifen to ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 There’s never a ... when it comes to non-emergency, minor illnesses. , As of ... 24/7 online access to medical care via the Internet. Patients ... smartphone, tablet or computer. , “Everyone is busy. We know ... a challenge, so we want to make it easier,” said ...
(Date:6/1/2015)... Texas (PRWEB) June 01, 2015 Carrick ... brain health landscape on a global level. This ... realms, allowing Carrick Brain Centers to broaden their scope ... healing. , Broadened horizons are accompanied by a restructuring ... 1, 2015, Carrick Brain Centers will separate itself from ...
(Date:6/1/2015)... 01, 2015 A University of ... inhibits signaling proteins that activate protein degradation, which ... exercise. 1 , The study published April ... male Spraque-Dawley rats 2-3 months of age who ... were given either whey protein (.4g/kg), low-dose Sustamine ...
Breaking Medicine News(10 mins):Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Carrick Brain Centers announces separation from Dr. Frederick Carrick to reflect the broader scope of impact and growth as an organization. 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 3
... PRINCETON, N.J., July 15 Diabetes patients taking ... insulin in their pump for up to six days following ... labeling change, diabetes care company Novo Nordisk announced today.(1) The ... pump reservoir for two days. This makes NovoLog((R)) the first ...
... likely to keep education a priority, research finds , ... more likely than their Chinese counterparts to lose interest ... children outperform Americans in academic pursuits such as math, ... and Chinese students in grades 7 and 8, more ...
... , WASHINGTON, July 15 Steele will ... spelling out what Republicans are for and what they are against while ... care plan would do for ordinary Americans. , ... , The Senate Health, Education, Labor and ...
... 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) ... preparing for the tender business of 250,000 doses of ... can be viewed by visiting this web page directly ... batch exported to Indonesia this year by the company. ...
... WASHINGTON, July 15 Speaker Nancy Pelosi issued the following ... health care reform legislation: , , ... the Senate HELP Committee is further evidence of great momentum in ... of trying, this puts us one step closer to real reforms ...
... , Recent Death of Infant in ... SILVER SPRING, Md., July 15 The American Society for Parenteral ... the science and practice of nutrition support therapy, is saddened by the recent ... to him through an IV catheter and not through a feeding tube in ...
Cached Medicine News:Health News:FDA Approves NovoLog(R) Labeling Update 2Health News:FDA Approves NovoLog(R) Labeling Update 3Health News:FDA Approves NovoLog(R) Labeling Update 4Health News:U.S. Students' Academic Interests Tend to Wane in Middle School 2Health News:Hard To Treat Diseases (HTDS.PK) Tender Order To Indonesia 2Health News:Tube Feeding Error: Fatal Medical Mistakes 2Health News:Tube Feeding Error: Fatal Medical Mistakes 3
The Shandon Linistain SLS Linear Stainer is an economical mid-size linear stainer for staining procedures that do not require heat....
... The Shandon Finesse E+ is ... provides automated specimen advance with ... balanced flywheel is easy to ... the user the option of ...
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
... is a service that directly connects ... the customers laboratory to the Thermo ... U.S.A., and Runcorn, U.K.* By using ... customer site, high-value support services are ...
Medicine Products: